Connective Tissue Growth Factor (CTGF) is highly expressed in patients with end-stage dilated cardiomyopathy (DCM).

We tested if CTGF inhibition with a monoclonal antibody prevents remodeling and preserves function in a mouse model of DCM.

CTGF inhibition improved left ventricular (LV) systolic and diastolic function and slowed the progression of LV dilatation.

Expression of many genes associated with tissue remodeling were elevated in DCM, but were decreased by CTGF inhibition.

However total collagen deposition and LV fibrosis were not attenuated.

These observations suggest that CTGF inhibition may benefit patients with DCM.